Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers

In BRG we are just starting Study for Healthy People with an Immune Drug - Part B. The aim of the following clinical trial is to determine safety and pharmacokinetic parameters in healthy volunteers after oral administration of Janus kinases and Rho-kinases inhibitor (JAK/ROCKi), called CPL409116.Janus kinase (JAK) inhibitors are a new class of small molecule drugs that modulate inflammatory pathways by blocking one or more JAK receptors. In recent years, JAK inhibitors have emerged as a new option for the treatment of various inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, skin disorders and others. CPL409116 inhibits JAK1 and JAK3 with less inhibitory activity against JAK2 and Tyk2. Inhibition of these kinases decreases inflammatory cytokine release which in turn decreases lymphocyte activation and proliferation. Moreover, CPL409116 blocks Rho-kinases (ROCKs), which are involved in diverse cellular processes including actin cytoskeleton organization, cell adhesion and motility, proliferation, apoptosis as well as smooth muscle contraction.  Dual inhibition of JAK/ROCK kinases may be beneficial for patients suffering from fibrotic complications of inflammatory disease. More information about the study you can find on https://clinicaltrials.gov/ct2/show/NCT04670757?term=CPL409116&draw=2&rank=1

Go back

News

Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic

BioResearch is following  new recommendations for sponsors on how to manage the conduct of clinical trials in the context of the coronavirus disease (COVID-19) pandemic..

Read more …

BRG update on COVID-19

Dear Investigators and Researchers.
In recent days, the whole world is providing heroic fight with the SARS-CoV-2 virus.

Read more …

International Clinical Trials Day

On 28th of June, 2019 we attended the annual conference on the occassion of International Clinical Trials Day titled "On the verge of changes".

Read more …

TransCelerate accreditation

To improve our trainings system, we joined „GCP Mutual Recognition Program" and were accredited by TransCelerate Biopharma Inc

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲